Lilly opens remote-controlled robotic lab

Jan. 16, 2020

Eli Lilly, in collaboration with Strateos, unveiled a new robotic laboratory in San Diego, California designed to accelerate the drug discovery process.

Strateos, which was formed last year from the merger of Transcriptic and 3Scan, will utilize their robotic cloud platform to enable the access of a remote-controlled lab to other drug discovery companies and research scientists through its secure cloud-based platform as part of the collaboration.

The 11,500 square foot lab, located within the Lilly Biotechnology Center, integrates several areas of the drug discovery process together — including design, synthesis, purification, analysis, sample management, and hypothesis testing — into a fully automated platform. The Strateos technology platform enables research scientists to remotely control their experiments via a web-based interface.

Through the studio lab, emerging drug discovery companies can gain access to a variety of tools and throughput usually reserved for much larger organizations. 

Read the press release